Contact: Feldman Strategies,

  Emma Thomas, 860-951-1167

               Andrew Feldman, 781-820-6650

STATEMENT: GenBioPro, Manufacturer of Generic Mifepristone, Responds to Texas Judge’s Ruling in AHM v. FDA and Washington Judge’s Ruling in Washington v. FDA

Las Vegas, NV – For more than 20 years, mifepristone has been FDA-approved for early abortion. FDA’s determination that mifepristone is safe and effective is in line with extensive studies and evidence, the expertise of the nation’s medical and scientific communities, as well as the regulatory determinations of national healthcare systems throughout the world. In 2019, GenBioPro received FDA approval for a generic mifepristone product and began offering this option to certified prescribers. Today, GenBioPro markets mifepristone across the United States for many healthcare settings. 

Statement from Evan Masingill, CEO of GenBioPro:

“Decades of science support mifepristone’s safety and efficacy. GenBioPro is reviewing two federal court orders. One issued by Judge Kacsmaryk and one by Judge Rice.  

With respect to Judge Kacsmaryk’s order, GenBioPro is not a party in that case but is nevertheless reviewing the court’s order in detail. Nothing in the court’s order changes the decades of science and evidence regarding mifepristone’s safety and efficacy. As we review the court’s order, we will continue to make our product available. We will take any steps necessary to lawfully make mifepristone available and accessible to as many people as possible in the country.  

We are additionally reviewing Judge Rice’s order and are pleased that he recognizes the importance of preserving the status quo as it relates to the availability of mifepristone.

The bottom line is, we are confident in the legality of mifepristone’s approval.

GenBioPro firmly believes that all people, regardless of income, gender, race, or geography, have a right to access evidence-based health care and safe and effective medicines, and that includes medication abortion.”